CONCLUSIONES
En resumen, la incidencia de ETVA en el subgrupo de enfermos ingresados en UCI por causa médica fue elevada. Estos pacientes acumulaban numerosos factores de riesgo de ETV y fueron ingresados por patologías con un contingente específico de enfermedad tromboembólica venosa (ETV) también muy elevado. La forma de presentación más habitual de ETVA fue la TVPA aislada, de aparición temprana y localización proximal y única. Y las principales causas de tromboprofilaxis farmacológica subóptima fueron las consideraciones de riesgo hemorrágico y/o insuficiencia renal.
BIBLIOGRAFÍA
1. Guijarro-Merino R, Montes J, San Román C. Epidemiología hospitalaria de la enfermedad tromboembólica venosa en España. Med Clin (Barc). 2008; 131 (Suppl 2):2-9.
2. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999; 353(9162):1386-1389.
3. Stein PD, Huang H, Afzal A, Noor HA. Incidence of acute pulmonary embolism in a general hospital. Relation to age, sex and race. Chest. 1999; 116(4):909-913.
4. Moser KM, Fedullo PF, LitteJohn JK, Crawford R. Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis. JAMA. 1994; 271(24): 223-225.
5. Girard P, Musset D, Parent F, Maitre S, Phlippoteau C, Simonneau G. High prevalence of detectable deep venous thrombosis in patients with acute pulmonary embolism. Chest. 1999; 116(4):903-908.
6. Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors Consensus Group. BMJ. 1992; 305(6853): 567-574.
7. Le Jeune S, Pistorius MA, Planchon B, Pottier P. Risk of venous thromboembolism in the course of acute medical illness. Part 1: Basic research, clinical models, descriptive and analytic epidemiology. Rev Med Interne. 2008; 29(6):452-461.
8. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, et al. The Prophylaxis in Medical Patients with Enoxaparin Study Group. A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients. N Engl J Med. 1999; 341(11):793-800.
9. Leizorovicz A, Cohen AT, Turpie CG, Olsson CG, Vaitkus PT, Goldhaber SZ. PREVENT Medical Thromboprofylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004; 110(7):874-879.
10. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness. Analysis of the Medenox Study. Arch Inter Med. 2004; 164(9):963-968.
11. Vaitkus PT, Leizorovicz A, Cohen AT, Turpie CG, Olsson CG, Goldhaber SZ. Prevent Medical Thromboprofylaxis Study Group. Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thromb Haemost. 2005; 93(1):76-79.
12. Monreal M, Kakkar AK, Caprini JA, Barba R, Uresandi F, Valle R, et al. RIETE Investigators.The outcome alter treatment of venous thromboembolism is diferent surgical and acutelly ill medical patients.Findings from RIETE Registry. J Thromb Haemost. 2004; 2(11):1892-1898.
13. Prandoni P,Villalta S, Bagatella P, Rossi L, Marchiori A, Picciolli A, et al.The clinical course of deep-vein trombosis.Prospective long-term follow-up of 528 symptomatic patients. Haematologica. 1997; 82 (4):423-428.
14. Kollef MH, Zahid M , Eisenberg PR . Predictive value of a rapid semiquantitative D-dimer assay in critically ill patients with suspected venous thromboembolic disease. Crit CareMed. 2000;28(2):414-420 .
15. Ibrahim EH, Iregui M, Prentice D, Sherman G, Kollef MH, Shannon W. Deep vein thrombosis during prolonged mechanical ventilation despite prophylaxis. Crit Care Med. 2002;30(4):771-774 .
16. Cook D, Crowther M, Meade M, Rabbat C, Griffifth J, Geerts W, et al. Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med.2005;33(7):1565-1571 .
17. Cook D, Douketis J, Meade M, Guyatt G, Zytaruk N, Granton J, et al. Canadian Critical Care Trials Group. Venous thromboembolism and bleeding in critically ill patients with severe renal insuffieciency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors. Crit Care. 2008;12(2): R32. Doi:10.1186/cc6810.
18. Shorr AF, Williams MD. Venous thromboembolism in critically ill patients. Observations from a randomized trial in sepsis. Thromb Haemost. 2009;101(1):139-144
19. Muscedere JG, Heyland DK, Cook D. Venous thromboembolism in critical illness in a community intensive care unit. J Crit Care.2007;22:285-289.
20. Chan CM, Shorr AF. Venous thromboembolism disease in the care unit. Semin Resp Crit Care Med. 2010; 31(1):39-46.
21. Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B et al for the Endorse Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (Endorse Study): a multifactorial cross-sectional study. Lancet.2008; 371:387-394.
22. Antithrombotic Therapy and Prevention of Thrombosis, 9th edition: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition). Chest. 2012; 141(2 Suppl):S15-S801.
23. Cohen AT, Edmnondson RA, Phillips MJ, Ward VP, Kakkar VV. The changing pattern of venous thromboembolic disease. Haemostasis. 1996; 26(2):65-71.
24. Lindblad B, Sternby NH, Berqvist D. Incidence of venous thormboembolism verified over 30 years. BMJ. 1991; 302(6778):709-711.
25 Dalen JE. Pulmonary embolism: what have we learned since Virchow? Natural history pathophysiology and diagnosis. Chest. 2002; 122(4):1440-1456.
26. PIOPED Investigators. Value of the ventilation/perfussion scan in acute pulmonary embolism. JAMA. 1990; 263(20):2753- 2759.
27. Tiseo M, Bersanelli M, Presenti Barilli M, Barlotti M, De Luca G, Gelsomino F, et al. Asymptomatic pulmonary embolism in lung cancer: prevalence and analysis of clinical and radiological characteristics in 141 outpatients. Tumori.2012;98(5):594-600.
28. Ray WZ, Strom RG, Blackburn SL, Ashley WW, Sicard GA, Rich Km. Incidence of deep venous thrombosis